• A new way to tackle aging could have the potential to upend a $20 billion market

    1 month ago - By Business Insider

    A new anti-aging therapeutic in the clinical pipeline could stand to disrupt multibillion-dollar legacy franchises like AbbVie's Humira and Amgen's Enbrel.
    This new type of therapeutic, called senolytics , is being developed by four biotech companies right now, and analysts think the first market-ready product could become available as early as 2023.
    Senolytics will be able to target all age-related diseases, eliminating the need for current therapeutics that are more limited in the range of diseases they can address.
    A new therapeutic treatment might be making its way to the anti-aging...
    Read more ...